The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
Open accessAbstract
Alemtuzumab is a humanized anti-CD52 antibody licensed for refractory B-cell chronic lymphocytic leukemia (B-CLL), when given intravenously at 30 mg thrice weekly. However, the intravenous route is associated with infusion-related reactions and is inconvenient. We measured blood concentrations in 30 relapsed patients treated with intravenous alemtuzumab and in 20 patients from a previously untreated group who received similar doses subcutaneously. Highest trough samples in the intravenous group were less than 0.5 μg/mL to 18.3 μg/mL (mean 5.4 μg/mL). The cumulative dose required to reach 1.0 μg/mL was 13 mg to 316 mg (mean 90 mg). Higher blood concentrations correlated with the achievement of better clinical responses and minimal residual disease. The highest measured concentrations in the subcutaneous group were similar (0.6 μg/mL to 24.8 μg/mL, mean 5.4 μg/mL). However, the cumulative dose to reach 1.0 μg/mL was higher: 146 mg to 1106 mg (mean 551 mg). No antiglobulin responses were detected in 30 patients given intravenous alemtuzumab whereas 2 of 32 patients given subcutaneous alemtuzumab made substantial anti-idiotype responses. Thus, subcutaneous alemtuzumab achieved concentrations similar to those for intravenous alemtuzumab, although with slightly higher cumulative doses. Subcutaneous alemtuzumab is more convenient and better tolerated but may be associated with some patients forming anti–alemtuzumab antibodies, particularly those patients who were previously untreated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Self-citation
Cited by
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Self-citationClinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
Cox, A. L., Thompson, S. A. J., Jones, J. L., Robertson, V. H., Hale, G., Waldmann, H., Compston, D. A. S., & Coles, A. J. (2005) · European Journal of Immunology · doi:10.1002/eji.200535075 · Cited by 291
Self-citationStilgenbauer, S., Zenz, T., Winkler, D., Bühler, A., Schlenk, R. F., Groner, S., Busch, R., Hensel, M., Dührsen, U., Finke, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1128 · Cited by 270
Metadata
- Authors
- Hale, G., Rebello, P., Brettman, L. R., Fegan, C., Kennedy, B., Kimby, E., Leach, M., Lundin, J., Mellstedt, H., Moreton, P., Rawstron, A. C., Waldmann, H., Osterborg, A., & Hillmen, P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-08-15
- Volume
- 104
- Issue
- 4
- Pages
- 948-955
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2102505853
- Cited by
- 182
- References
- 1
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. https://app.cochat.ai/papers/10.1182/blood-2004-02-0593
- The paper
- Hale, G., Rebello, P., Brettman, L. R., Fegan, C., Kennedy, B., Kimby, E., Leach, M., Lundin, J., Mellstedt, H., Moreton, P., Rawstron, A. C., Waldmann, H., Osterborg, A., & Hillmen, P. (2004). Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood. https://doi.org/10.1182/blood-2004-02-0593
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.